From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: SBTX

Search articles by EPIC code

SkinBioTherapeutics – no-one watching o’clock results and equity raise, what’s the outlook from here?

SkinBioTherapeutics (SBTX) has announced no-one watching o’clock (4:30pm) results for its year ended 30th June 2022, with CEO Stuart Ashman stating “this financial year has been a mixed one for the group”. With the results coming with a potentially £3.5 million equity raise (albeit including an up to £1 million “retail offer”) at 16p per share, we’ve got some other words for it but where does this all leave the company now?

I am branded Mr Angry - Lemming Investor video interview with Stuart Ashman of Skinbiotherapeutics

Let us be clear. When I said that Staurt Ashman said that month on month sales doubled in both July and August I said so because the bearded loon said so in an email to me. For him to backtrack as he does in this interview and suggest that "Mr Angry" is a bit confused, therefore makes me a bit more er....angry. If you have an hour of your life to spare, enjoy.


SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

Page 1 of 5 (50 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments